Phase 3, single-center, sequential and parallel-group, double-blind, randomized study evaluating the efficacy and safety of Fexofenadine Hydrochloride 180 mg (Allegra®/Telfast®) versus placebo in subjects suffering from seasonal Allergic Rhinitis with symptoms aggravated in presence of pollutants - Ellis, Anne K.; Murrieta-Aguttes, Margarita; Furey, Sandy; Carlsten, Christopher (The World Allergy Organization journal, 2020)